Amsterdam, The Netherlands - May 31, 2007 - Amsterdam Molecular Therapeutics (AMT), a leader in the field of human gene therapy, reported positive Phase I/II clinical trial results with its lead product AMT-010 (now referred to as AMT-011) in Complete Lipoprotein Lipase (LPL) deficient patients at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT) in Seattle. The study's lead investigator is Erik S.G. Stroes, MD, PhD, from the University of Amsterdam Medical Center in The Netherlands.
